Trials / Completed
CompletedNCT01215799
Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer
A Phase II Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- CytRx · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase II open-label study evaluating the preliminary efficacy and safety of bafetinib administered as 240 mg orally twice daily in subjects with Hormone Refractory Prostate Cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bafetinib | Bafetinib 240 mg bid |
Timeline
- Start date
- 2010-08-01
- Primary completion
- 2011-09-01
- Completion
- 2011-12-01
- First posted
- 2010-10-07
- Last updated
- 2011-12-15
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01215799. Inclusion in this directory is not an endorsement.